Y Yu1,2, E Gool1,2,3, R J Berckmans1,2, F A W Coumans2,3, A D Barendrecht4, C Maas4, N N van der Wel5, P Altevogt6,7, A Sturk1,2, R Nieuwland1,2. 1. Laboratory of Experimental Clinical Chemistry, Academic Medical Centre (AMC) of the University of Amsterdam, Amsterdam, the Netherlands. 2. Vesicle Observation Centre, AMC, Amsterdam, the Netherlands. 3. Department of Biomedical Engineering and Physics, AMC, Amsterdam, the Netherlands. 4. Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, the Netherlands. 5. Department of Medical Biology, Electron Microscopy Centre Amsterdam, AMC, Amsterdam, the Netherlands. 6. Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany. 7. Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Heidelberg, Germany.
Abstract
Essentials Human salivary extracellular vesicles (EVs) expose coagulant tissue factor (TF). Salivary EVs expose CD24, a ligand of P-selectin. CD24 and coagulant TF co-localize on salivary EVs. TF+ /CD24+ salivary EVs bind to activated platelets and trigger coagulation. SUMMARY: Background Extracellular vesicles (EVs) from human saliva expose coagulant tissue factor (TF). Whether such TF-exposing EVs contribute to hemostasis, however, is unknown. Recently, in a mice model, tumor cell-derived EVs were shown to deliver coagulant TF to activated platelets at a site of vascular injury via interaction between P-selectin glycoprotein ligand-1 (PSGL-1) and P-selectin. Objectives We hypothesized that salivary EVs may deliver coagulant TF to activated platelets via interaction with P-selectin. Methods We investigated the presence of two ligands of P-selectin on salivary EVs, PSGL-1 and CD24. Results Salivary EVs expose CD24 but PSGL-1 was not detected. Immune depletion of CD24-exposing EVs completely abolished the TF-dependent coagulant activity of cell-free saliva, showing that coagulant TF and CD24 co-localize on salivary EVs. In a whole blood perfusion model, salivary EVs accumulated at the surface of activated platelets and promoted fibrin generation, which was abolished by an inhibitory antibody against human CD24. Conclusions A subset of EVs in human saliva expose coagulant TF and CD24, a ligand of P-selectin, suggesting that such EVs may facilitate hemostasis at a site of skin injury where the wound is licked in a reflex action.
Essentials Human salivary extracellular vesicles (EVs) expose coagulant tissue factor (TF). Salivary EVs expose CD24, a ligand of P-selectin. CD24 and coagulant TF co-localize on salivary EVs. TF+ /CD24+ salivary EVs bind to activated platelets and trigger coagulation. SUMMARY: Background Extracellular vesicles (EVs) from human saliva expose coagulant tissue factor (TF). Whether such TF-exposing EVs contribute to hemostasis, however, is unknown. Recently, in a mice model, tumor cell-derived EVs were shown to deliver coagulant TF to activated platelets at a site of vascular injury via interaction between P-selectin glycoprotein ligand-1 (PSGL-1) and P-selectin. Objectives We hypothesized that salivary EVs may deliver coagulant TF to activated platelets via interaction with P-selectin. Methods We investigated the presence of two ligands of P-selectin on salivary EVs, PSGL-1 and CD24. Results Salivary EVs expose CD24 but PSGL-1 was not detected. Immune depletion of CD24-exposing EVs completely abolished the TF-dependent coagulant activity of cell-free saliva, showing that coagulant TF and CD24 co-localize on salivary EVs. In a whole blood perfusion model, salivary EVs accumulated at the surface of activated platelets and promoted fibrin generation, which was abolished by an inhibitory antibody against humanCD24. Conclusions A subset of EVs in human saliva expose coagulant TF and CD24, a ligand of P-selectin, suggesting that such EVs may facilitate hemostasis at a site of skin injury where the wound is licked in a reflex action.
Authors: Wariya Sanrattana; Simone Smits; Arjan D Barendrecht; Nadine D van Kleef; Hinde El Otmani; Minka Zivkovic; Mark Roest; Thomas Renné; Chantal C Clark; Steven de Maat; Coen Maas Journal: J Thromb Haemost Date: 2021-10-29 Impact factor: 16.036
Authors: Lisa N van der Vorm; Joost E I G Brouwers; Ceráya Mondria; Bas de Laat; Philip G de Groot; Jasper A Remijn Journal: Res Pract Thromb Haemost Date: 2018-07-20